Genie Fertility

Genie Fertility is a London-based, pre-clinical reproductive-health biotech developing what it describes as the first non-invasive fertility diagnostic for the uterus. Its first test analyses a range of molecular markers in the endometrium (uterine lining) using menstrual blood, which the company characterises as the monthly shedding of the whole uterine lining and a source of reproductive data not obtainable from a standard blood draw. The stated clinical rationale is that endometrial health can account for up to a quarter of fertility issues but is routinely overlooked because it can otherwise only be assessed by an invasive, expensive biopsy that samples a small portion of the lining.

Underpinning the test is a machine learning multi-omics discovery platform. Company materials and press coverage state the platform was built on data from more than 200,000 fertility patients; the company website separately cites an 11,999+ patient dataset powering the platform. The company says it has identified a number of novel fertility markers in the uterine lining that can be acted on through existing medical pathways, and it intends to use the platform to generate a pipeline of further diagnostics and targeted therapeutics for reproductive conditions including polycystic ovary syndrome, endometriosis and perimenopause/menopause.

The company is led by co-founder and CEO Anoushka Menon and co-founder and CTO Dr Andreas Hadjimitsis, with Dr Yifan Wang as founding scientist. Its advisory bench includes Dr Sotirios Saravelos (Imperial College London NHS Trust), Dr Sylvain Ladame (Imperial College London), Professor Hanno Steen (Harvard University/Harvard Medical School), Professor Eva Dimitriadis (University of Melbourne), Assistant Professor Matteo A. Molè and Dr Efstathios Theodorou (Centre for Reproductive and Genetic Health).

Founding story

Hadjimitsis completed a PhD in Imperial College London's Department of Bioengineering, working on 3D printing of biomaterials for diagnostic applications, and previously worked with synthetic biology startup CorNatural and advised a US venture capital fund on biotechnology investments. He joined Entrepreneurs First, where he met Anoushka Menon, who studied genetics at the University of Cambridge before moving into reproductive health at home-diagnostics company Thriva Health and the women's health platform The Lowdown, and who commercialised the first at-home fertility test in the UK. The pair bonded over shared experience of reproductive health issues and the field's chronic underfunding, and decided to combine backgrounds in laboratory science, computation and women's health. A central technical insight was that menstrual blood contains the same uterine cells otherwise obtained by biopsy and can be used as a non-invasive sampling route, previously underused because the specimen is variable and difficult to process.

Business model

Genie Fertility is a pre-clinical diagnostics developer. Its near-term product is a diagnostic test delivered in the fertility care setting, with results reported to clinicians so they can adjust treatment to improve the chance of conception. Longer term, the company intends to use its discovery platform to develop additional diagnostics and targeted therapeutics for reproductive conditions.

Traction

Pre-clinical stage. A small pilot was followed by clinical studies starting in March 2025 with repeat patient sample donations; collaborations are in place with leading IVF groups in the UK and Europe; and a nine-month longitudinal pregnancy-outcome study is funded by the pre-seed round. No revenue, customer count or regulatory clearance figures are disclosed in the sources.

Latest developments

Following the September 2025 launch and pre-seed round, the company began deploying capital toward validation of its first diagnostic and a nine-month longitudinal study of pregnancy outcomes, plus further development of its ML model. A March 2026 interview with co-founder Andreas Hadjimitsis described the company as focused on IVF in the near term while building foundational molecular understanding of the uterus to support earlier diagnosis, disease stratification and drug-target identification for endometriosis, PCOS and menopause.